



Rec'd PCT/PTO 22 SEP 2004

PCT/EP 03 / 02990

Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

10 / 508766

REC'D 19 MAY 2003

WIPO PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02006490.3

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

BEST AVAILABLE COPY



Anmeldung Nr:
Application no.: 02006490.3
Demande no:

Anmeldetag:
Date of filing: 22.03.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Amynon Biotech GmbH
Schneeberggasse 76A
6020 Innsbruck
AUTRICHE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Anti-HPV-16 E7 antibody and its use

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07K16/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

22 März 2002

New EP-Patent Application
Amynon Biotech GmbH
Our Ref.: G1279 EP

Anti-HPV-16 E7 antibody and its use

The present invention relates to an anti-HPV-16 E7 antibody obtainable by (a) eliciting an in vivo humoral response against native, highly purified HPV-16 E7 protein or a fragment thereof in a non-human vertebrate; and (b) affinity-purifying antibodies as obtained in the eliciting-step (a). Furthermore, the invention provides for the use of the anti-HPV-16 E7 antibody/antibodies for the preparation of a diagnostic composition for the (immuno-) histological detection of expressed HPV-16 E7 in a biological sample. Additionally, the invention relates to diagnostic compositions as well as to methods for producing the same. The invention also provides for kits comprising (an) anti-HPV-16 E7 antibody(ies) of the invention or a diagnostic composition of the invention and discloses in vitro methods for the detection of a sexually transmittable disease or cancer, in particular cervical cancer or prostate cancer by using the described antibodies.

Despite an intensive screening program, cervical cancer is one of the most predominant neoplastic diseases in women with a world-wide incidence second only to breast cancer (Walboomers, 1999). A major etiological factor in the genesis of cervical carcinoma is the infection by human papillomaviruses (HPVs), which are small DNA viruses that infect epithelial cells of either the skin or mucosa. Of the almost 100 different types of HPV that have been characterised to date, approximately two dozen specifically infect genital and oral mucosa (reviewed in zur Hausen, 2000). On the basis of epidemiological and biochemical data, HPVs are subdivided into two groups. Genital HPVs of the high-risk group (most commonly HPV-16, 18) cause cervical cancer, while other anogenital cancers and papillomaviruses of the low-risk group (most frequently HPV-6, 11) cause benign genital warts (for review, see Howley, 1996). PCR based studies have shown that more than 99 % of invasive cervical cancers world-wide contain high risk HPVs (Walboomers, 1999); however, malignant progression occurs only in a small subset of infected patients and is typically slow (reviewed in Alexander and Phelps, 2000). Most cervical dysplasia represent squamous cell carcinoma and the main diagnostic

tool to detect cervical dysplastic cells is still based on cytological screening using Pap-smear analysis introduced in 1943 by Papanicolaou (1942) (for review, see Koss, 1989; Meijer and Walboomers, 2000). Although Pap-smear analysis has proven highly effective it is difficult to standardise, which is reflected by a high false negative error rate of approximately 30 % (Walboomers, 1995; Clavel, 1999; Renshaw et al., 2001). Despite the introduction of mass screening programs, the best of which have dropped the mortality rates by 70%, incidence of cervical cancer in the United States has been increasing by about 3% a year since 1986 in spite of an intensification of the rate of screening (Larsen, 1994).

Since it is medical general knowledge that cervical cancer arises as consequence of persistent high-risk papillomavirus infections (reviewed in zur Hausen, 2000), the problem could be addressed by the introduction of HPV tests into screening programmes for better identification of patients at risk. At present, for clinical applications, PCR and the hybrid capture analysis, both are DNA-detecting methods, are only useful to a limited extend (reviewed in Milde-Langosch, 2000). Milde-Langosch furthermore teaches that, besides the molecular biological methods, some antibodies against early HPV-proteins are sold (for example by Santa Cruz Biotechnology or Dianova) but these antibodies are, in comparison to these molecular biological techniques even less sensitive in (immuno)-histochemical analysis.

The major disadvantage of the above discussed molecular biology methods systems is, that they do only allow to detect viral infection, however, about 5-30% of the normal female population harbours these viruses and only very few of these develop clinically relevant lesions (von Knebel Doeberitz, 2001). In accordance with this consideration, a high rate of transient and asymptomatic HPV infections was found especially among young woman (Schiffman and Brinton, 1995). Given the low incidence of cervical cancer, it may not be useful to apply HPV detection for cervical cancer screening in this age group. Moreover, the PCR based screening systems, although highly sensitive, are not widely applied for the reason that HPV DNA will be detected in a wide range of normal cytological smears resulting in a high rate of false positive amplification (reviewed in Trofatter, 1997).

It is well established that the expression of E6 and E7, in epithelial stem cells of the mucosa, is required to initiate and maintain cervical carcinogenesis (for recent review, see Mantovani and Banks, 2001; Münger, 2001). Thus, a promising way to improve the screening programs could be to measure the expression of the E6 and E7 oncoprotein which initiate in a long term process neoplastic transformation in few of the HPV harbouring cells. Since these viral proteins are not expressed in normal cervical squamous epithelia, screening for high risk E7 over-expressing cells allows to specifically identify dysplastic lesions. Moreover, progression of pre-neoplastic lesions to invasive cervical cancers is often associated with a continuous enhanced expression of the E6 and E7 oncoprotein (Schwarz, 1985; Francis, 2000). Similar to these considerations, Klaes (2001) monitored the overexpression of the cyclin-dependent kinase inhibitors p16 (INK4a), a gene which is upregulated in response to E7, as a marker for dysplastic and neoplastic epithelial cells of the cervix uteri. However, p16 (INK4A) is only one of several genes which are upregulated in response to E7 (for review, see McMurray, 2001) and upregulation of p16 (INK4A) expression is not necessary for E7 induced malignant transformation (Giarre, 2001). Furthermore, in view of its central role as tumorsuppressor and cell cycle inhibitory protein p16 (INK4A) is upregulated by several other, growth suppressing, stimuli, thus p16 (INK4a) is for example well known as target of senescence-inducing pathways (for review, see Bringold and Serrano, 2000). Consequently upregulation of p16 (INK4A) might not necessarily reflect the activity of the E7 oncoprotein:

Furthermore, some studies have speculated on the prevalence of anogenital types of human papillomavirus in prostate cancer and benign prostate hypertrophy. Interestingly, the prevalence of an HPV, in particular HPV-16 infection in prostate carcinogenesis is highly disputed. Cuzick (1995, *Cancer Sarr.* 23, 91-95) review earlier reports on this issue and stress that it is unlikely that common anogenital papillomaviruses have an important role in prostate carcinogenesis. Several studies have linked the presence of HPV16 DNA to a risk for developing prostate cancer (e.g. Moyret-Lalle, 1997, *Int. J. Cancer* 64, 125-129; Jerris, 1997 *Urology* 50, 150-156 or Suzuki, 1996, *Prostate* 28, 318-324), yet, these studies did not provide for a conclusive relationship between prostate cancerogenesis and HPV-16 activities and/or the expression of HPV16 proteins. Wideroff (1996, *Prostate* 28, 117-123) even teaches that HPV infection is not a significant risk factor for prostate cancer and

Anderson (1997, J. Med. Virol. 52, 8-13) confirms the teaching that HPV16 and closely related types are unlikely initiators of prostate cancer. Similarly Noda (1998, Urol. Res. 26, 165-169) suggests that HPV is not a causal factor for prostatic cancer or benign prostatic hyperplasia, and Stickler (1998, Cancer 82, 1118-1125 and 1998, Eur. J. Canc. Prev. 7, 305-313) comes to the conclusion that HPV is not associated with prostate carcinomas. Even if Serth (1998) analysed by single-tube quantitative, competitive PCR samples from prostate cancers and indicates that in accordance with this DNA-detection method, HPV16 might contribute to the development of a subset of prostate cancers (Serth (1999), Canc. Res. 59, 823-825), another study of the same year (Saad (1999), Can. J. Urol. 6, 834-838) could not detect HPV DNA in fresh tissue from patients undergoing radical prostatectomy for prostate cancer. Accordingly, the role of HPVs, in particular HPV16, in prostate cancer remains controversial and elusive.

Several sets of monoclonal antibodies against the HPV-16 E7 oncoprotein or HPV-16 E7 derived peptides have been produced (Sato, 1989; Tindle, 1990; Selvey, 1992; Stacey, 1994; Fujikawa, 1994; Zatsepina, 1997) and commercial preparations are also available (Zymed Laboratories, San Francisco, CA, USA; Santa Cruz Biotechnology, Santa Cruz, CA, USA). No antibody, however, was reported as sufficient in sensitivity and specificity to recognise HPV-16 E7 neither in cytological smears nor in paraffin embedded sections from biopsies of cervical cancer patients; see Milde-Langosch, 1999. Di Lonardo (2001, Arch Viral 146, 117-125) has produced egg yolk antibodies as well as rabbit antibodies against E7 oncogenic protein of HPV16. Di Lonardo (2001), loc. cit. stresses that some commercial preparations of anti-E7 antibodies are available, but they suffer severe disadvantages and are not suitable for diagnostic purposes. Yet, the data provided by Di Lonardo (2001) are not conclusive since merely the hen antibodies were able to localize HPV-16 E7 in a cultured cell line and in a SIL (Squamous Intraepithelial lesion) biopsy. However, Di Lonardo (2001) loc. cit. also teaches that the rabbit antibodies are not able to detect E7 in immunocytochemistry and stressed that the generated hen antibodies were in a number of cases unable to detect E7 protein in immunostainings of cervical lesions.

Accordingly, there is a need in the art for means and methods which provide for reproducible assays for the detection of symptomatic HPV infections for the detection

of the malignant state of a cancerous cell or for the detection of a sexually transmittable disease.

Thus, the technical problem underlying the present invention is to comply with the needs described above.

In accordance, the present invention provides for an anti-HPV-16 E7 antibody obtainable by

- a) eliciting an in vivo humoral response against native, highly purified HPV-16 E7 protein or a fragment thereof in a non-human vertebrate; and
- b) affinity-purifying antibodies as obtained in the eliciting-step (a).

The term "anti-HPV-16 E7 antibody" as employed herein refers to an antibody, a plurality of antibodies and/or a serum comprising such antibodies which is/are able to specifically bind to, interact with or detect the E7 oncoprotein of HPV16 or a fragment thereof. Said term also relates to a purified serum, i.e. a purified polyclonal serum. The antibody molecule is preferably a full immunoglobulin, like an IgG, IgA, IgM, IgD, IgE, IgY (for example in yolk derived antibodies). The term "antibody" as used in this context of this invention also relates to a mixture of individual immunoglobulins. Furthermore, it is envisaged that the antibody/antibody molecule is a fragment of an antibody, like an F(ab), F(abc), Fv Fab' or F(ab)₂. Furthermore, the term "antibody" as employed in the invention also relates to derivatives of the antibodies which display the same specificity as the described antibodies. Such derivatives may, inter alia, comprise chimeric antibodies or single-chain constructs. Yet, most preferably, said "anti-HPV-16 E7 antibody" relates to a serum, more preferably a polyclonal serum and most preferably to a purified (polyclonal) serum. The antibody/serum is obtainable, and preferably obtained, by the method described herein and illustrated in the appended examples.

The term "eliciting an in vivo humoral response in a non-human vertebrate" relates to the provocation of an immune response in a non-human vertebrate, in particular the provocation of an antibody response to HPV-16 E7 or a fragment thereof. Said antibody response comprises primary as well as secondary antibody responses to the antigenic challenge with HPV-16 E7 or a fragment thereof. The term "eliciting an

in vivo humoral response", accordingly, relates to the provocation of an immune reaction involving the production of antibodies directed towards the antigen, namely HPV-16 E7 or a fragment thereof.

The term "native, highly purified HPV-16 E7 protein or a fragment thereof" relates to an isolated HPV-16 E7 protein or fragment thereof, which has been purified to a purity level of at least 95%, more preferably of at least 96%, even more preferably of at least 97%, particularly preferred of at least 98% and most preferably of at least 99% purity. The purity of HPV-16 E7 protein may be confirmed by methods known in the art, preferably by densitometrical analysis as illustrated in Verdoliva (2000, J. Chromatogr. B. Biomed. Sci. Appl. 279, 233-242) or Aboagye-Mathiesen (1992, Prep. Biochem. 22: 105-121) and most preferably as described in the appended examples.

Preferably said native HPV-16 E7 protein or a fragment thereof is recombinantly produced and, preferably, said protein or fragment thereof lacks further modifications like additional tags, like His-tags or GST-tags.

In accordance with this invention, the term "native HPV-16 E7 protein" relates to a protein which is correctly folded or relates to a stretch/fragment of said protein which is correctly folded and which is soluble, preferably highly soluble. It is in particular preferred that the native HPV-16 E7 protein comprises equivalent amounts of zinc, which is required for correct secondary structure of the E7 protein. It is of note that the term "native HPV-16 E7 protein" also comprises naturally occurring variants of HPV-16 E7 protein. Such variants are known in the art, as, inter alia, described by Sang Song (1997, Gynecologic Oncology 66, 275-281) or by Ku (2001), Dis. Of Colonand Rectum 44, 236-242.

The term "fragment of HPV-16 E7 protein" as used herein relates to fragments of a length of at least 50, more preferably at least 60, even more preferably at least 65 amino acid residues of the native HPV-16 E7 protein. The amino acid sequence of HPV-16 E7 and of corresponding variants is known in the art and published in Seedorf (1987, EMBO J. 6, 139-144), Sang Song (1997, loc. cit.) or Ku (2001, loc.

cit.). Most preferably, said fragment comprises at least the stretch of amino acids 33 to 98 of HPV-16 E7 as disclosed in Seedorf (loc. cit.).

Preferably, the recombinantly produced HPV-16 E7 protein or its fragment is expressed in a prokaryotic host, preferably in *E. coli*. Yet, also other expression systems are envisaged which comprise:

Bacterial expression systems, for example, pET System, P_L Expression System, pCAL Vectors, pGEX Vectors, PRO Bacterial Expression System or Yeast expression systems, like pESP Vectors, pESC Vectors, Pichia Expression system, YES Vector collection, SpECTRA *S. pombe* Expression System, pYD1 System or Insect expression systems, like BacPAK System, Bac-to-Bac Baculovirus Expression System, Bac-N-Blue Baculovirus Expression System, DES: The Drosophila Expression System, Insectselect System or Viral expression systems, like AdEasy Adenoviral Vector System, AAV Helper-Free System ViraPort Retroviral Gene Expression System, Adeno-X Expression System, pLXSN System or Mammalian expression systems, like pMSG System, pCMV Script, pCI, Creator Gene Cloning & Expression System, Tet-On; Tet-Off Gene Expression System.

As illustrated in the appended example, preferably, said highly purified HPV-16 E7 protein or a fragment thereof is purified by a combination of ion exchange chromatography and gel filtration and said purification may further comprise, prior to ion exchange chromatography and gel filtration, a protein precipitation step.

Ion exchange chromatography is known to the artisan and ion exchange media comprise, but are not limited to Mini beads Q, Source 15 Q, Source 30 Q, Sepharose High Performance Q, Sepharose Fast Flow Q, Sepharose XL Q, Sepharose Big Beads Q, DEAE, Streamline DEAE (all from Amersham Biosciences, Vienna, Austria), DEAE-cellulose, QA-cellulose, CM-cellulose, SE-cellulose, DE-52 (Whatman, Kent, England) or Agarose based ion exchangers. Most preferably a Mono QHR 10/10 column (Amersham Biosciences, Vienna, Austria) is employed.

Gel filtration systems and media are also known to the skilled artisan which comprise Superdex peptide, Superdex 30, Superdex 200, Superose 6, Superose 12, Sephacryl, Sphadex (all from Amersham Biosciences, Vienna, Austria), Biogel P,

Agarose-gel, Fracto-gel or Ultro-gel. A most preferred gel filtration system, also employed in the appended examples, is a HiLoad 16/60 Superdex 75 gel filtration column.

Protein precipitation techniques comprise, inter alia, Dextran sulphate-, Polyethylene glycol (PEG) 4000 - 8000-, Acetone-, Protamine sulphate-, Streptomycin sulphate-, pH-shift-precipitations. Preferably, said protein precipitation is carried out by ammonium sulfate precipitation. Most preferably a 30% saturated $(\text{NH}_4)_2\text{SO}_4$ -solution is employed.

Accordingly, an example of such a purification method is a three step purification comprising: 1. protein precipitation, 2. ion exchange chromatography 3. gel filtration. As illustrated in appended example 2, which comprises more details, this precipitation method may preferably be carried out by an ammonium sulfate precipitation using 30 % saturated $(\text{NH}_4)_2\text{SO}_4$ solution, an ion exchange chromatography using a Mono Q HR10/10 column (Amersham Biosciences, Vienna, Austria) and a gel filtration using a HiLoad 16/60 Superdex 75 gel filtration column (Amersham Biosciences, Vienna, Austria)

It is also envisaged that, as step before the protein precipitation or in addition to the protein precipitation, the crude cell lysate is centrifuged, for example at 70 000 x g for 1 hour.

As mentioned herein above, the antibodies obtained after eliciting an immune response against the highly purified HPV-16 E7 or a fragment thereof are further purified, in particular affinity purified. Preferably, said affinity purification of the obtained antibodies is carried out over immobilized HPV-16 E7 protein or a fragment thereof. Most preferably, said HPV-16 E7 protein or a fragment thereof is immobilized on PVDF membranes, nitrocellulose, sepharose, agarose, DEAE-cellulose or DEAE. As illustrated in the appended examples, one possibility of affinity purifying the HPV-16 E7 or a fragment thereof comprises the immobilization of HPV-16 E7 or said fragment on PVDF membranes. Immobilized HPV-16 E7 protein is incubated with the polyclonal HPV-16 E7 antiserum, washed, and the affinity purified antibodies are eluted by an acid gradient from the immobilized HPV-16 E7 protein.

The elution of bound anti-HPV-16 E7 antibodies may be carried out by methods known in the art which, inter alia, comprise acid gradients or salt gradients.

In a particularly preferred embodiment, the HPV-16 E7 protein is prepared as described in Examples 1 and 2, appended hereto.

Most preferably, the "non-human vertebrate" mentioned herein above is selected from the group consisting of rat, mouse, rabbit, chicken, sheep, horse, goat, pig and donkey. Most preferably said vertebrate is a chinchilla bastard rabbit.

The antibodies of the present invention provide for the first time a reliable tool in the (immuno)-histochemical detection of an HPV-16 E7 infection and/or in cancer diagnostic. The antibodies provided herein are, inter alia, useful in the direct measurement of expressed E7 oncoprotein in biological samples, for example in Pap-smears, samples from cervix biopsies, low or high grade squamous, intraepithelial lesions, in samples from prostate biopsies, in particular from fine needle aspiration biopsies.

It was surprisingly found that the anti-HPV-16 E7 antibodies produced according to the above-described method are, in contrast to antibodies of the prior art, capable of reliably detecting expressed E7 in a variety of biological samples. It is of particular note that the antibodies of the invention are also capable of detecting E7 in fixed material, e.g. in formaldehyde-fixed biological samples. The detection is also possible in paraffin- or frozen sections of biological samples and tissue. As documented in the appended examples, the described antibodies may be employed in (immuno)-histological techniques, like immunostainings of biological tissue (e.g. cervix tissue) or in probes derived from fine needle aspiration biopsies (e.g. prostate tissue).

Accordingly, the present invention provides for improved diagnostic tools for the detection of an HPV-16 infection. The antibodies of the present invention are in particular useful for the detection of HPV-16 E7 in Pap-smears.

The detection of, e.g., enhanced E7 oncoprotein expression level by the provided antibody(ies) allows to identify pre-neoplastic lesions with a particularly high risk for malignant progression and invasive cancers on histological probes and/or in cytological smears. This helps to improve current limitations in cancer screening, diagnosis, and therapy control, in particular in cervical and prostate cancer. The

described antibodies provide for useful tools in the classification of sexually transmitted diseases or of cancer. Furthermore, these antibodies against highly purified HPV-16 E7 protein or a fragment thereof recognise the HPV-16 E7 oncoprotein in neoplastic cells derived from, e.g., cervical smears, in paraffin- or in frozen-sections from biopsies of patients. Thus, these antibodies have major diagnostic potential as markers of malignant transformation in, inter alia, carcinogenesis, e.g. cervical carcinogenesis or prostate carcinogenesis.

The antibodies described herein have major advantages over the antibodies of the prior art, e.g. commercially available antibodies as, inter alia, provided by Santa Cruz Biotechnologies. In contrast to antibodies and antibody-reagents provided by the prior art, the antibody/antibodies described herein are highly specific and do not provide for high number of "false-positive" signals, i.e. of a "positive" immunobiochemical signal in samples or cells which are HPV-16 negative or which do not express the HPV-16 E7 protein or a fragment thereof. As illustrated in the appended examples the antibodies of the invention may be, inter alia, tested for this reliability in transfection studies. For example, cultured cells, preferably human U2-OS cells may be transfected with a vector heterologously expressing E7, for example a vector which provides for CMV-driven expression of HPV-16 E7. As a negative control, further U2-OS-cells may be transfected with an expression vector which does not express said E7 protein. "False positive" signals are evaluated by the amount of cells which are not transfected with the E7-expressing vector, but which, nevertheless, give a positive signal in immunobiological screenings, e.g. immunofluorescence microscopy. Preferably, less than 15%, more preferably less than 10%, even more preferably less than 5%, most preferably none of the cultured cells which do not (transiently or permanently) express E7-proteins ("negative control cells") are stained by the antibody described herein.

The invention also provides for the use of an anti-HPV-16 E7 antibody of the invention for the preparation of a diagnostic composition for the (immuno-) histological detection of expressed HPV-16 E7 in a biological sample. Preferably, said (immuno-) histological detection is carried out on Pap-smears (cervical smears), cervical (carcinoma) biopsies or prostate biopsies, like fine needle aspiration biopsies.

Most preferably said diagnostic composition is used for evaluating the acquisition of a sexually transmitted disease or the risk of developing cancer, for measuring the status of an existing sexually transmitted disease or cancer, or for screening the therapy efficiency in the treatment of a sexually transmitted disease or cancer.

Furthermore, the invention relates to a method for the preparation of a diagnostic composition comprising the step of formulating the inventive anti-HPV-16 E7 with a diagnostically acceptable carrier, diluent, buffer, or storage solution. It is also envisaged that in the use or the method of the present invention, said diagnostic composition further comprises suitable means for detection, for example secondary labelled antibodies or fragments thereof.

A variety of techniques are available for labeling biomolecules, are well known to the person skilled in the art and are considered to be within the scope of the present invention. Such techniques are, e.g., described in Tijssen, "Practice and theory of enzyme immuno assays", Burden, RH and von Knippenburg (Eds), Volume 15 (1985), "Basic methods in molecular biology"; Davis LG, Diber MD; Battey Elsevier (1990), Mayer et al., (Eds) "Immunochemical methods in cell and molecular biology" Academic Press, London (1987), or in the series "Methods in Enzymology", Academic Press, Inc.

There are many different labels and methods of labeling known to those of ordinary skill in the art. Examples of the types of labels which can be used in the present invention include enzymes, radioisotopes, colloidal metals, fluorescent compounds, chemiluminescent compounds, and bioluminescent compounds. Preferred are labels to be detected in immunohistochemical techniques.

Commonly used labels comprise, inter alia, fluorochromes (like fluorescein, rhodamine, Texas Red, Cy3, Cy5, etc.), enzymes (like, peroxidase, horse radish peroxidase, β -galactosidase, alkaline phosphatase), radioactive isotopes (like ^{32}P or ^{125}I), biotin, digoxigenin, colloidal metals, chemi- or bioluminescent compounds (like dioxetanes, luminol or acridiniums). Labeling procedures, like covalent coupling of enzymes or biotinyl groups, iodinations, phosphorylations, biotinylations, etc. are well

known in the art. It is of note that the antibodies of the invention may also be detected by secondary methods, like Indirect immuno-fluorescence. Accordingly, detectably labeled secondary antibodies may be employed in the methods and uses of the present invention.

As mentioned above, direct and indirect detection methods comprise, but are not limited to, fluorescence microscopy, direct and Indirect enzymatic reactions and the detection by microscopic means. Commonly used detection assays comprise radioisotopic or non-radioisotopic methods. These comprise, inter alia, Westernblotting, overlay-assays, RIA (Radioimmuno Assay) and IRMA (Immune Radioimmunometric Assay), EIA (Enzyme Immuno Assay), ELISA (Enzyme Linked Immuno Sorbent Assay), FIA (Fluorescent Immuno Assay), and CLIA (Chemiluminescent Immune Assay).

Accordingly, the invention also provides for a diagnostic composition comprising the anti-HPV-16 E7 antibody of the invention or obtained by the method of the invention

Said diagnostic composition may comprise the antibody molecules of the present invention, in soluble form/liquid phase but it is also envisaged that said antibodies are bound to/attached to and/or linked to a solid support.

Solid supports may be used in combination with the diagnostic composition as defined herein or the antibodies, antibody fragments or antibody derivatives of the present invention may be directly bound to said solid supports. Such supports are well known in the art and comprise, inter alia, commercially available column materials, polystyrene beads, latex beads, magnetic beads, colloid metal particles, glass and/or silicon chips and surfaces, nitrocellulose strips, membranes, sheets, duracytes, wells and walls of reaction trays, plastic tubes etc. The antibodies of the present invention may be bound to many different carriers. Examples of well-known carriers include glass, polystyrene, polyvinyl chloride, polypropylene, polyethylene, polycarbonate, dextran, nylon, amyloses, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble or insoluble for the purposes of the invention. Appropriate labels and methods for labeling have been identified above.

In a further embodiment the invention provides for a kit comprising an anti-HPV-16 E7 antibody of the invention or a diagnostic composition of the invention.

Advantageously, the kit of the present invention further comprises, optionally (a) buffer(s), storage solutions and/or remaining reagents or materials required for the conduct of medical, scientific or diagnostic assays and purposes. Furthermore, parts of the kit of the invention can be packaged individually in vials or bottles or in combination in containers or multicontainer units. The kit may also comprise an instruction sheet to carry out the (diagnostic) methods of the present invention.

The kit of the present invention may be advantageously used, inter alia, for carrying out the (diagnostic) methods of the invention and could be employed in a variety of applications referred herein, e.g., as diagnostic kits, as research tools or medical tools. Additionally, the kit of the invention may contain means for detection suitable for scientific, medical and/or diagnostic purposes, like e.g. secondary antibodies as described above. The manufacture of the kits follows preferably standard procedures which are known to the person skilled in the art.

In another aspect the present invention relates to an in vitro method for the detection of a sexually transmittable disease or cancer comprising the steps of

- (a) incubating a biological sample with anti-HPV-16 E7 antibodies of the invention;
and
- (b) measuring and/or detecting specifically-bound anti-HPV-16 E7 antibodies
whereby the presence, the absence or the amount of specifically-bound anti-HPV-16 E7 antibodies is indicative for said sexually transmittable disease or cancer. It is further preferred that this in vitro method comprises a further step (c), whereby in said step (c) the presence, the absence or the amount of specifically-bound anti-HPV-16 E7 antibodies of step (b) is compared to the presence, the absence or the amount of specifically-bound anti-HPV-16 E7 antibodies in a negative or a positive control sample or in both control samples.

The measurement and/or detection of specifically "bound anti-HPV-16 E7 antibodies" may be carried out as described above, for example by the detection of directly or indirectly labelled, bound antibody molecules of the invention. Said measuring and

detection methods may also comprise automated and/or computer-controlled detection methods.

Such in vitro methods of the invention are also illustrative in the appended examples and may be, inter alia, employed to detect the presence or absence of an HPV16 infection, to evaluate whether a HPV16 infection is merely transient or an asymptomatic HPV16 infection. It is of note that the antibodies of the present invention may be employed in the above described method in order to evaluate the absence or presence of a proliferative disorder, like, e.g. cervix carcinoma. Furthermore, the antibodies may be employed to evaluate the class of a proliferative disorder, for example it can be evaluated whether a prostatic carcinoma is HPV16 dependent or independent. It is, e.g., envisaged that patients whose serum comprises prostatic-specific antigen (PSA) or who have a positive result in fine-needle aspiration biopsies of prostatic tissue are further examined for the presence or absence of HPV-16 E7, employing the antibodies of the invention and methods disclosed herein. Such a diagnostic method allows for the distinction of HPV16-positive and HPV16-negative prostate carcinomas and the medical intervention may be chosen accordingly.

As mentioned above, the biological sample is preferably a cervix or a prostatic sample; most preferably a Pap-smear or a fine needle aspiration biopsy.

In contrast to previous technology, namely the detection of HPV-16 DNA in prostate cancer biopsies, the detection of high-level HPV-16 E7 expression in prostate cancer samples allows the conclusion that in these samples the E7 oncoprotein, which is the major transforming protein of the virus, is actively expressed. The person skilled in the art knows that expression of the E7 oncoprotein in any cell results in the inactivation of several important tumor suppressor mechanisms, as reviewed in Zwerschke (2000, Adv. Cancer Res. 78, 1-29). This indicates that there is a high risk for malignant progression of this lesion. It has to be stressed that currently physicians do not consider HPV-dependent malignant progression of prostate cancers, since detection of HPV oncoproteins in prostate cancer specimens was not possible with the techniques of the prior art. The antibodies described herein allow significant progress in clinical research. Furthermore, it is anticipated that with the advent of specific antiviral drugs directed against high-risk papillomaviruses, the detection of

HPV-16 E7 in prostate cancer specimens will direct the physician to new modes of treatment for this important malignancy.

The invention, accordingly, provides for the use of an anti-HPV-16 E7 antibody, a diagnostic composition or a kit of the invention in an in vitro method for the detection of a sexually transmittable disease or cancer. Said sexually transmitted disease is, preferably an HPV16-infection or said cancer is cervical cancer or prostate cancer.

In another embodiment, the present invention provides for a method for production of an anti-HPV-16 E7 antibody comprising the steps of

- (a) eliciting an in vivo humoral response against native, highly purified. HPV-16 E7 protein or a fragment thereof in a non-human vertebrate; and
- (b) affinity-purifying antibodies as obtained in the eliciting-step (a).

With respect to the preferred embodiments the same applies, mutatis mutandis, as described herein above for the anti-HPV-16 E7 antibody.

The Figures show:

Figure 1: Purification of the HPV-16 E7 oncoprotein. Bacterial expressed recombinant HPV-16 E7 was step wise purified by ammonium sulfate precipitation, anion-exchange chromatography on MonoQ and gel filtration on a Sephadex G75 column. (A, B) Samples were separated by gel electrophoresis, and purification was documented by coomassie staining of the fractions as indicated. Purity of the HPV-16 E7 protein was confirmed by Western blotting using a monoclonal anti E7 antibody (Santa Cruz, Vienna, Austria) (C).

Figure 2: Test of the affinity purified anti-HPV-16 E7 antibodies (14/3) in western blot analysis. A. Purified GST and GST-HPV-16 E7 proteins were separated by SDS-polyacrylamide gel electrophoresis, and the GST-HPV-16 E7 protein was detected by western blotting. B. The HPV-16 E7 expressing cells E7/2 and the control cells were subjected to lysis. Subsequently lysates were separated by SDS-polyacrylamide gel electrophoresis and

probed with antibodies to HPV-16 E7 and beta actin (input control), as indicated.

Figure 3: Detection of HPV-16 E7 after transient expression in human cells. U-2OS cells were transiently transfected with expression vectors for HPV-16 E7, as indicated. At 26 h post transfection, cells were processed for indirect immunofluorescence microscopy and viewed by using a confocal scanning system. Cells were stained with anti-E7 antibodies clone 14/3 (α -HPV-16 E7), preimmune serum (control), TroPro3 (nucleus) or both anti-E7 antibodies and TroPro3 (α -HPV-16 E7/nucleus), as indicated.

Figure 4: Immunoperoxidase staining of paraffin sections of normal cervix and cervical carcinomas with affinity purified polyclonal antibodies against HPV-16 E7. Paraffin sections of normal cervix and a cervical carcinoma were immunostained for HPV-16 E7 by the immunoperoxidase method as described in material and methods. (A) In cervical carcinoma tissue, epithelial cells are negative with the preimmunserum. (B, C, E, G) In cervical carcinoma tissues anti-HPV-16 E7 antibodies stain virtually all cells in the tumor islets. (D) In normal cervical tissue, epithelial cells are negative with these antibodies. (F) In cervical carcinoma tissues staining by the anti-HPV-16 E7 antibodies can be competed out by preincubation of the antibodies with purified HPV-16 E7 antigen. (H) Control, no staining of cervical carcinoma tissues was obtained by adding only the horse radish conjugated secondary anti rabbit IgG.

Figure 5: Immunoperoxidase staining of cells obtained from prostate carcinoma patients. Biopsies were taken from 60 prostate carcinoma patients and samples from 60 patients were applied to an object slide together with negative controls. These slides are known to the expert as "tissue microarrays" (Skacel, 2002, Appl. Immunohistochem. Mol. Morphol. 10, 1-6). Tissue micorarrays were stained with antibodies to HPV-16 E7 as described in Fig. 4 for cervical biopsies. In this experiment, a subset of the carcinoma biopsies stained positive for HPV-16 E7, whereas other biopsies from different prostate cancer patients stained negative.

The invention is illustrated by the following examples:

Example 1: Construction of the bacterial expression vector for HPV-16 E7

The HPV-16 E7 oncogene was amplified from the vector pX-HPV-16 E7 (Mannhardt et al., 2000) by PCR using Pfu DNA polymerase as EcoRI repair / BamHI fragment. The sequence was inserted into the bacterial expression vector pET3a (Studier and Moffatt, 1986) prepared as NdeI repair / BamHI fragment generating the bacterial HPV-16 E7 expression vector pET3a-HPV-16 E7/clone 17. The sequence encoding for HPV-16 E7 was verified by sequencing.

Example 2: Expression and purification of recombinant HPV-16 E7 protein

The expression vector pET3a-HPV-16 E7/clone 17 was transformed into *E. coli* strain BL21 (DE3) pLysS. The bacteria were grown to $OD_{600}=0.5$ and the expression of the E7 protein was induced for 3 hours at 37 C° by adding IPTG (Biomol, Hamburg, Germany) to a final concentration of 0.4 mM. Bacteria were harvested by centrifugation for 10 minutes at 5 000 x g. The cell pellets were frozen in 20 ml ice-cold lysis buffer (50 mM KCl, 20 mM H₂KPO₄ [pH 7.8], 50 mM DTT, 5 % glycerol, 1 µg/ml leupeptin, 1 mM PMSF, 1 mM NaF and 10 µg/ml Aprotinin) per liter bacterial culture. Cells were thawed on ice and lysed by sonication with glass beads (Sigma, Vienna, Austria) using a Sonifier 250 (Branson, Geneva, Switzerland). After centrifugation at 70 000 x g for 1 hour, the supernatant was ammonium sulfate precipitated using 30 % saturated (NH₄)₂SO₄ solution. The (NH₄)₂SO₄ pellet was dissolved in 4 ml MonoQ loading buffer (150 mM Tris/Cl pH 7.8, 10 mM NaCl, 10 mM DTT and 5 % glycerol) and dialysed against MonoQ loading buffer. The dialysed probe was centrifuged at 10 000 x g for 10 minutes and loaded onto a MonoQ HR10/10 column (Amersham Biosciences, Vienna, Austria) via a 10 ml SuperLoop (Amersham Biosciences, Vienna, Austria). Using a linear salt gradient the E7 protein eluted from the anion-exchange-column at 600 mM NaCl. 15 fractions were collected. The E7 containing fractions were pooled and loaded onto a HiLoad 16/60 Superdex 75 gel filtration column (Amersham Biosciences, Vienna, Austria) and run with the gelfiltration buffer (150 mM Tris/Cl pH 7.8, 150 mM NaCl and 10 mM DTT).

At a flow of 0.5 ml/min. Gels were stained with Coomassie brilliant blue and the stained gel was evaluated by scanning, using the Adobe Photoshop Software and a MicroTec Scan Maker 8700 Image Scanning Device. This generated a profile of relative optical density which was used to determine the integral corresponding to the E7 peak. With this software it is possible to calculate the percentage of total OD units which are represented by the E7 peak. As judged by densitometrical analysis the E7 fractions resulting from this run were >99,5 % pure and were concentrated using a Centriprep10 ultrafiltration filter (Amicon, Vienna, Austria). The identity of the E7-protein was confirmed by Western Blot (Fig. 1B) and through a peptide mass fingerprint (PMF) (Fig.1C).

Example 3: Generation of polyclonal HPV-16 E7 Antibodies:

Purified preparations of the HPV-16 E7 protein were used to produce highly specific polyclonal anti-HPV-16 E7 antibodies in chinchilla bastard rabbits (Charles River, Germany). 1st injection: 700 µl complete Freund's adjuvant (Sigma, Vienna, Austria) was mixed with 500 µg HPV-16 E7 protein dissolved in 700 µl PBS by sonication (Branson sonifier 250, level 5-7, 3 X 10 seconds). A total of 300 µg HPV-16 E7 protein was injected. 1st boost: 32 days after the first injection, 500 µl complete Freund's adjuvant was mixed with 500 µg 16 E7 protein dissolved in 500 µl PBS by sonication. A total of 500 µg HPV-16 E7 protein was injected. 2nd boost: 28 days after the first boost, 500 µl incomplete Freund's adjuvant was mixed with 500 µg 16E7 protein dissolved in 500 µl PBS by sonication and a total of 500 µg HPV-16 E7 protein was injected. 3rd boost: 27 days after the second boost, 500 µl incomplete Freund's adjuvant was mixed with 500 µg 16 E7 protein dissolved in 500 µl PBS by sonication. A total of 500 µg HPV-16 E7 protein was injected. Bleeding was done 10 days after the third boost.

Example 4: Affinitypurification of polyclonal HPV-16 E7 Antibodies:

Glutathione-S-transferase (GST-HPV-16 E7) and GST (control) were expressed from the expression vectors pGEX4T-GST-HPV-16 E7 and pGEX4T (Mannhardt, 2000; Mol Cell Biol 20:6483-95) in the *E. coli* strain DH5α. Expression was induced by adding IPTG to a final concentration of 1 mM to a 200 ml bacterial culture at

$OD_{600}=1.0$. The bacteria were washed once in PBS and lysed in PBSDT (1.5 mM KH_2PO_4 , 8.1 mM Na_2HPO_4 [pH 7.4], 2.7 mM KCl, 137 mM NaCl, 0.2 mM phenylmethylsulfonyl fluoride [PMSF], 1 mM NaF, 1 mM dithiothreitol [DTT] and 0.5 % Triton X-100) by sonication using a Branson sonifier 250. The lysates were centrifuged at 4 000 x g for 10 minutes and afterwards at 30 000 x g for 30 minutes to remove the cell debris. The recombinant proteins were purified by affinity-chromatography using the glutathione sepharose 4B system (Amersham, Vienna, Austria). Clear supernatants were incubated for 3 hours at 4 °C with 150 μ l glutathione sepharose 4B beads, which were prior, equilibrated in cold (4 °C) PBSDT. After the binding interval the beads were washed 4 times in 5 ml of PBSDT and stored at 4 °C in PBSDT. Purity of the preparation was controlled by western blotting using an anti E7 antibody (clone ED17, Santa Cruz, Vienna, Austria) and by Coomassie staining. Aliquots of 200 μ g of bound GST proteins were separated on a 12.5 % SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane (NEN, Boston, USA) by electro blotting. PVDF membranes were dried and the proteins were crosslinked to the membrane by UV irradiation. The protein bands were stained with Ponceau S solution, excised from the PVDF membrane, destained and transferred to microfuge tubes.

Subsequently, the fragments were incubated with the polyclonal rabbit HPV-16 E7 antiserum for 2 hours at room temperature and washed 3 times in PBS-T (1.5 mM KH_2PO_4 , 8.1 mM Na_2HPO_4 [pH 7.4], 2.7 mM KCl, 137 mM NaCl and 0.5 % (vol/vol) Tween 20). Each fragment was then eluted by three 30 seconds washes with 5 mM glycine-HCl, [pH 2.3], 500 mM NaCl, 0.5 % (vol/vol) Tween 20, 10 μ g/ml BSA in volumes of 500 μ l; these eluates were immediately neutralized by the addition of Na_2PO_4 to a final concentration of 50 mM. The purified antibodies were concentrated 4 times using a centriprep YM-3 centrifugal filter (Millipore Corporation, Bedford, USA). After the pH 2.3 elution, fragments were further washed with three similar aliquots of PBS-T and 10 μ g/ml of BSA, followed by three washes with 3 M NH_4SCN , 150 mM KCl, 10 mM $NaPO_4$ [pH 6.0], and 10 mg/ml BSA. The procedure was repeated 5 times.

Example 5: Test of the affinity purified HPV-16 E7 antibodies

The affinity purified HPV-16 E7 antibodies specifically recognize HPV-16 E7 in cell lysates from HPV-16 E7 expressing mammalian cells in western blot experiments (Fig. 1). HPV-16 E7 was also detectable in human U-2-OS cells transiently transfected with a HPV-16 E7 expression vector by indirect immunofluorescence microscopy using the confocal scanning system (Fig. 2). Furthermore, the antibodies recognize HPV-16 E7 in immunohistochemical experiments done in paraffin-embedded sections of cervical carcinomas derived from biopsies of HPV-16 positive patients (Fig. 3). Biopsies from 12 carcinoma patients were analyzed and positive signals were obtained with the E7 antibody in all 12 cases. Furthermore, in two cases of cervix biopsies which had previously been classified by PCR-methods as "HPV-16 negative", the antibody described herein was able to specifically detect expressed E7.

Example 6: Western blot (immunoblot) analysis

Cell extracts were separated on a 12.5 % sodium dodecyl sulfate (SDS)-polyacrylamide gel, and proteins were transferred to a PVDF membrane (NEN, Boston, USA). The membrane was incubated in blocking buffer (0.05 % Tween 20 / 5 % low-fat milk powder in PBS) for 1 hour at room temperature, washed in blocking buffer and incubated with the first antibody (affinity purified polyclonal rabbit anti-HPV-16 E7 antibody) for 1 hour at room temperature. After washing in blocking buffer, PBS/0.05 % Tween 20 and PBS/5 % low fat milk powder the membrane was incubated with the second antibody (peroxidase-conjugated anti-rabbit IgG, Promega, Mannheim, Germany) for 45 minutes at room temperature. The membrane was washed, and the bound antibodies were visualized by using the chemiluminescence Western blotting detection system (NEN, Boston, USA).

Example 7: Indirect Immunofluorescence analysis

U-2-OS cells were cultured in DMEM + 10 % FCS. For transient expression of cDNAs, cells were grown to about 80 % confluence on glass coverslips coated with 0.05 % gelatin. Transfection of the expression vector pJ4HPV-16 E7 (Massimi, et al.,

(1997) J. Gen. Virol. 78, 2607-2613) was performed by using Effectene (Qiagen, Hilden, Germany). 24 h post-transfection, cells were prepared for indirect immunofluorescence according to standard protocols, including methanol fixation. After incubation with the primary antibody (affinity purified polyclonal rabbit anti-HPV-16 E7 antibody), and secondary antibody (FITC-conjugated anti-rabbit IgG, Dianova, Hamburg, Germany), cells were washed and embedded in Fluoromount G (Biozol, Eching, Germany). Samples were viewed by indirect immunofluorescence microscopy using the confocal scanning system MicroRadiance (Bio-Rad, Munich, Germany) in combination with a Zeiss Axiophot microscope. The following filters were used for FITC-derived fluorescence: excitation at 488 nm, emission at 515-530 nm). In these experiments, HPV-16 E7 were detected in 5-10% of the transfected cells, whereas no signal was obtained in cells that have been transfected with the empty expression vector. This result clearly proves that the antibody is specific for the E7 protein and does not detect any non-specific background under these conditions. The superior properties of the antibodies of the invention can be furthermore illustrated in the following experiment: To calibrate the antibodies, human U2OS cells were transfected with a CMV-driven expression vector for HPV-16 E7 and the staining of transfected cells by the antibodies as described herein was compared to the staining pattern obtained with commercially available antibodies from SantaCruz Biotechnology. Staining was analysed by indirect immunofluorescence and evaluated by confocal microscopy. In these experiments, the commercially available antibodies (obtained from SantaCruz Biotechnology) gave high background staining in all cells, which prevented the detection of E7 antigene in the transfected cells. In contrast, the antibodies according to the invention detect positive signals in 5-10% of the transfected cells and reveal no signal in cells transfected by an empty expression vector. These results indicate that the antibodies described herein recognize only the E7 protein, whereas the commercially available antibodies used in the study recognize unrelated antigens in the preparation. When tested in immunohistochemical stainings, there was a high and apparently non-specific background obtained with the antibodies obtained from SantaCruz Biotechnology in tissues derived from cervix carcinoma patients, as well as in tissue derived from normal cervix. Furthermore, the positive signals obtained with the SantaCruz antibodies were not restricted to the area that is cytologically recognized as tumor tissue, but were also present in the non-tumor tissue. In contrast to these

results, staining of the biopsy material by the antibody according to the invention yielded positive results only for HPV-16 positive patients. As can be seen in Fig. 1, staining was clearly confined to the area of the tumor.

Example 8: Immunohistochemical detection of HPV-16 E7 in biopsies derived from cervical carcinomas

Immunohistochemistry was performed on paraffin-embedded sections of HPV16 positive biopsies derived from cervical carcinomas and control tissue specimens. The paraffin-embedded tissue specimens were sectioned at 5 μ m. Sections were mounted on slides, deparaffinized in xylol (2 x 10 minutes), incubated for 5 minutes each in 100 %, 90 %, 80 % and 70 % ethanol and blocked in 5 % H₂O₂ in absolute methanol for 15 minutes. Before immunostaining the sections were washed twice in TRIS buffer (7.75 g Tris-HCl pH 7.5, 8.78 g NaCl ad 1 liter aqua dest) and processed for a 15 minutes blocking reaction in diluted (1:10 in TRIS buffer/1 %BSA) goat-serum (DAKO, Hamburg, Germany). Sections were washed in TRIS/1%BSA buffer and incubated with the first antibody (affinity purified polyclonal rabbit anti-HPV-16 E7 antibody) for 1 hour at room temperature in buffer B (10 μ g/ml BSA / 10 μ g/ml NIH3T3 lysate in PBS). The samples were rinsed twice in TRIS/1 %BSA buffer and incubated for 1 hour at room temperature with the second antibody (Biotin-conjugated anti-rabbit IgG, DAKO, Glostrup, Denmark). After the washing step in TRIS/1 %BSA, ExtrAvidin-conjugated peroxidase solution (Amersham Biosciences, Vienna, Austria) was added and the samples were incubated for 1 hour at room temperature, rinsed in TRIS buffer and processed for staining. Bound antibodies were visualized with DAB (3,3'-diaminobenzidine) (Sigma, Vienna, Austria) as substrate chromogen. Slides were counterstained with Hemalaun and coverslipped using Eukitt (Merck; Darmstadt, Germany). Brightfield microscopy with photography was performed using a Leica DMRB microscope and a Nikon Coolpix 995 camera.

Example 9: Immunohistochemical detection of HPV-16 E7 in prostate derived tissue

Biopsies were taken from 60 prostate carcinoma patients and samples from 60 patients were applied to an object slide together with negative controls. These slides

are known to the expert as "tissue microarrays". Tissue microarrays were stained with antibodies to HPV-16 E7 as described in Fig. 5 for cervical biopsies. In this experiment, a subset of the carcinoma biopsies stained positive for HPV-16 E7, whereas other biopsies from different prostate cancer patients were staining negative. In these experiments, HPV-16 E7 was detected in roughly 10% of the prostate carcinoma specimens analyzed. This result suggests that the subset of the prostate carcinomas express high levels of HPV-16 E7 and thereby provide evidence for a role of HPV-16 E7 in prostate carcinoma.

References

- Alexander and Phelps (2000) *Expert Opin. Investig. Drugs* **9**: 1753-65
- Bringold, (2000) *Exp Gerontol* **35**:317-29
- Clavel, (1999) *Br J Cancer* **80**:1306-11
- Francis, (2000) *J Virol* **74**:2679-86
- Fujikawa, (1994) *Virology* **204**: 789-793
- Giarre, (2001) *J Virol* **75**:4705-12
- Howley, (1996) *Fields Virology*, 3rd edn. Lippincott-Raven, Philadelphia, PA, pp. 2045-2076.
- Klaes, (2001) *Int J Cancer* **92**:276-84
- Koss, (1989) *J. Am. Med. Assoc.* **261**: 737-743
- Larsen, N. S. (1994) *J. Natl. Cancer Inst.* **86**: 6-7
- McMurray, (2001) *Int J Exp Pathol* **82**:15-33
- Meijer, (2000) *J Clin Pathol* **53**:41-3
- Milde-Langosch, (2000) *Virchows Arch* **437**:227-33
- Milde-Langosch, (1999) *Pathologe* **20**:15-24
- Mantovani, (2001) *Oncogene* **20**:7874-87
- Münger, (2001) *Oncogene* **20**:7888-98
- Papanicolaou, (1942) *Science* **95**: 438-439
- Renshaw, (2001) *Cancer* **93**:106-10
- Sato, (1989) *Virology*: **170**: 311-314
- Schiffman, (1995) *Cancer* **76**:1888-1901
- Schwarz, (1985) *Nature* **314**:111-114
- Selvey (1992) *J Virol Methods* **37**: 119-127

- Stacey, (1994) *Oncogene* **9**: 635-645
- Studier, (1986) *J Mol Biol* **189**:113-30
- Tindle, (1990) *Peptide Res* **3**: 162-166
- Trofatter, (1997) *Jr. Am J Med* **102**:21-7
- Serrano, (1997) *Exp Cell Res* **237**:7-13
- von Knebel Doeberitz, (2001) *Dis Markers* **17**:123-8
- Walboomers, (1995) *J Clin Pathol* **48**:728-32
- Walboomers, (1999) *J Pathol* **189**:12-9
- Zatsepina, (1997) *Oncogene* **14**:1137-45
- zur Hausen, (2000) *J. Natl. Cancer Inst* **92**: 690-8



Claims

22 März 2002

1. An anti-HPV-16 E7 antibody obtainable by
 - (a) eliciting an in vivo humoral response against native, highly purified HPV-16 E7 protein or a fragment thereof in a non-human vertebrate; and
 - (b) affinity-purifying antibodies as obtained in the eliciting-step (a).
2. The anti-HPV-16 E7 antibody of claim 1, wherein said native, highly purified HPV-16 E7 protein or a fragment thereof is recombinantly produced.
3. The anti-HPV-16 E7 antibody of claim 2, wherein said HPV-16 E7 protein or said fragment thereof is expressed in E. coli.
4. The anti-HPV-16 E7 antibody of any one of claims 1 to 3, wherein said highly purified HPV-16 E7 protein or a fragment thereof is purified by a combination of ion exchange chromatography and gel filtration.
5. The anti-HPV-16 E7 antibody of claim 4, wherein said purification further comprises, prior to ion exchange chromatography and gel filtration, a protein precipitation step.
6. The anti-HPV-16 E7 antibody of any one of claims 1 to 5, wherein said affinity purification of the obtained antibodies is carried out over immobilized HPV-16 E7 protein or a fragment thereof.
7. The anti-HPV-16 E7 antibody of claim 6, wherein said HPV-16 E7 protein or a fragment thereof is immobilized on PVDF membranes, nitrocellulose, sepharose, agarose, DEAE-cellulose or DEAE.
8. The anti-HPV-16 E7 antibody of anyone of claims 1 to 7, wherein said non-human vertebrate is selected from the group consisting of rat, mouse, rabbit, chicken, sheep, horse, goat, pig and donkey.

9. Use of an anti-HPV-16 E7 antibody of any one of claims 1 to 8 for the preparation of a diagnostic composition for the (immuno-) histological detection of expressed HPV-16 E7 in a biological sample.
10. The use of any one of claims 9, wherein said (immuno-) histological detection is carried out on Pap-smears, cervical (carcinoma) biopsies or prostate biopsies.
11. The use of claim 9 or 10, wherein said diagnostic composition is used for evaluating the risk of acquiring a sexually transmitted disease or cancer, for measuring the status of an existing sexually transmitted disease or cancer, or for screening therapy efficiency in the treatment of a sexually transmitted disease or cancer.
12. A method for the preparation of a diagnostic composition comprising the step of formulating the anti-HPV-16 E7 antibody of any one of claims 1 to 8 with a diagnostically acceptable carrier, diluent, buffer, or storage solution.
13. The use of any one of claims 9 to 11 or the method of claim 12, wherein said diagnostic composition further comprises suitable means for detection.
14. A diagnostic composition comprising the anti-HPV-16 E7 antibody of any one of claims 1 to 8 or obtained by the method of claim 12 or 13.
15. Kit comprising an anti-HPV-16 E7 of any one of claims 1 to 8, or a diagnostic composition of claim 14.
16. An in vitro method for the detection of a sexually transmittable disease or cancer comprising the steps of
 - a) incubating a biological sample with anti-HPV-16 E7 antibodies of any one of claims 1 to 8; and
 - b) measuring and/or detecting specifically-bound anti-HPV-16 E7 antibodieswhereby the presence, the absence or the amount of specifically-bound anti-

HPV-16 E7 antibodies is indicative for said sexually transmittable disease or cancer.

17. The in vitro method of claim 17 further comprising a further step (c), whereby in said step (c) the presence, the absence or the amount of specifically-bound anti-HPV-16 E7 antibodies of step (b) is compared to the presence, the absence or the amount of specifically-bound anti-HPV-16 E7 antibodies in a negative or a positive control sample.
18. Use of an anti-HPV-16 E7 antibody of any one of claims 1 to 8, a diagnostic composition of claim 14 or a kit of claim 15 in an in vitro method for the detection of a sexually transmittable disease or cancer.
19. The in vitro method of claim 16 or 17 or the use of claim 11 or claim 18 wherein said sexually transmitted disease is an HPV16-infection or wherein said cancer is cervical cancer or prostate cancer.
20. A method for the production of an anti-HPV-16 E7 antibody comprising the steps of
 - (a) eliciting an in vivo humoral response against native, highly purified HPV-16 E7 protein or a fragment thereof in a non-human vertebrate; and
 - (b) affinity-purifying antibodies as obtained in the eliciting-step (a).


THIS PAGE BLANK (USPTO)

Abstract**22. März 2002**

The present invention relates to an anti-HPV-16 E7 antibody obtainable by (a) eliciting an in vivo humoral response against native, highly purified HPV-16 E7 protein or a fragment thereof in a non-human vertebrate; and (b) affinity-purifying antibodies as obtained in the eliciting-step (a). Furthermore, the invention provides for the use of the anti-HPV-16 E7 antibody/antibodies for the preparation of a diagnostic composition of the (immuno-) histological detection of expressed HPV-16 E7 in a biological sample. Additionally, the invention relates to specific diagnostic compositions as well as to methods producing the same. The invention also provides for kits comprising (an) anti-HPV-16 E7 antibody(ies) of the invention or a diagnostic composition and discloses in vitro methods for the detection of a sexually transmittable disease or cancer, in particular cervical cancer or prostate cancer by using the described antibodies.

22. März 2002


Fig. 1A

Purification of bacterially produced E7 via MonoQ-column
15% PAGE

2/16

Fig. 1B


G75 - Gelfiltration
15% PAGE



3/16

Fig. 1C


Western Blot
SantaCruz _-E7 1:500



Westernblot α -HPV-16 E7 Antibody (14/3)

4/16

Fig. 2A



Westernblot α -HPV-16 E7 Antibody

α -E7 14.3/aff.pur.

E7/ sc 6981

E7/2 NIH E7/2
a 3T3 w


E7/2 NIH E7/2
a 3T3 w



beta-actin

E7

Fig. 3



7/16

Fig. 4A

Paraffin section: HPV-16 DNA positive cervical carcinoma

Control Immunserum




8/16

Fig. 4B

Paraffin section: HPV-16 DNA positive cervical carcinoma

α -HPV-16 E7




9/16

Fig. 4C

Paraffin section stained with α -HPV-16 E7 (14/3)

HPV-16 DNA positive cervical carcinoma




10/16

Fig. 4D

Paraffin section stained with α -HPV-16 E7 (14/3)

Negative control normal squamous epithelium




11/16

Fig. 4E

Paraffin section: HPV-16 DNA positive cervical carcinoma

α -HPV-16 E7




12/16

Fig. 4F

Paraffin section: HPV-16 DNA positive cervical carcinoma

α -HPV-16 E7/Competition 1 μ g/ μ l 16 E7




13/16

Fig. 4G

Paraffin section: HPV-16 DNA positive cervical carcinoma

α -HPV-16 E7



14/16

Fig. 4H

Paraffin section: HPV-16 DNA positive cervical carcinoma


no. 1 antibody



15/16

Fig. 5


E7-positives Prostata-Ca.



16/16

Fig. 5 cont.

E7-negatives Prostata-Ca.



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.